Difference between revisions of "Entrectinib (Rozlytrek)"
m |
m |
||
| Line 17: | Line 17: | ||
==History of changes in Health Canada indication== | ==History of changes in Health Canada indication== | ||
*2020-02-10: Initial notice of compliance with conditions for the treatment of adult patients with unresectable locally advanced or metastatic extracranial [[:Category:Malignant solid neoplasm|solid tumours]], including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options. | *2020-02-10: Initial notice of compliance with conditions for the treatment of adult patients with unresectable locally advanced or metastatic extracranial [[:Category:Malignant solid neoplasm|solid tumours]], including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options. | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2019-06-18: Newly indicated for the treatment of NTRK fusion gene positive advanced or recurrent [[:Category:Malignant solid neoplasm|solid tumours]]. | ||
==Patient Drug Information== | ==Patient Drug Information== | ||
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf Entrectinib (Rozlytrek) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf Entrectinib (Rozlytrek) Package Insert]</ref> | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf Entrectinib (Rozlytrek) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf Entrectinib (Rozlytrek) Package Insert]</ref> | ||
| Line 39: | Line 41: | ||
[[Category:EMA approved in 2020]] | [[Category:EMA approved in 2020]] | ||
[[Category:Health Canada approved in 2020]] | [[Category:Health Canada approved in 2020]] | ||
| + | [[Category:PMDA approved in 2019]] | ||
Revision as of 15:28, 8 June 2023
General information
Class/mechanism, from the NCI Drug Dictionary: An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 2019-08-15: Granted accelerated approval for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Based on ALKA-372-001, STARTRK-1, and STARTRK-2)
- 2019-08-15: Approved for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (Based on ALKA-372-001, STARTRK-1, and STARTRK-2)
History of changes in EMA indication
- 2020-07-31: Initial conditional authorization
History of changes in Health Canada indication
- 2020-02-10: Initial notice of compliance with conditions for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.
History of changes in PMDA indication
- 2019-06-18: Newly indicated for the treatment of NTRK fusion gene positive advanced or recurrent solid tumours.
Patient Drug Information
Also known as
- Code name: RXDX-101
- Brand name: Rozlytrek